Spectral Diagnostics (OTCMKTS:EDTXF – Get Free Report) is expected to release its results before the market opens on Friday, November 6th. Analysts expect the company to announce earnings of ($0.0070) per share and revenue of $0.42 million for the quarter.
Spectral Diagnostics Stock Down 10.8%
Spectral Diagnostics stock opened at $0.66 on Wednesday. Spectral Diagnostics has a twelve month low of $0.64 and a twelve month high of $1.10. The firm has a 50 day moving average price of $0.83 and a 200-day moving average price of $0.95. The company has a market capitalization of $193.76 million, a P/E ratio of -6.58 and a beta of 0.21.
Spectral Diagnostics Company Profile
Spectral Diagnostics Inc is a Canadian medical technology company focused on improving the diagnosis and treatment of sepsis and septic shock. The company develops products designed to identify endotoxin activity, an important factor in certain severe infections and inflammatory conditions.
Its principal diagnostic product is the Endotoxin Activity Assay, a blood test intended to measure a patient’s level of endotoxin activity and help identify individuals who may be at increased risk of developing severe sepsis.
Read More
- Five stocks we like better than Spectral Diagnostics
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
